Hodgkin Lymphoma Clinical Trials

38 studies are recruiting for hodgkin lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

   This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Minnesota, Minneapolis, Minnesota

   Locations

   6 in total

   Run by

   Veronika Bachanova

   See if you can join NCT03681561 on ClinicalTrials.gov

2. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

   The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

   Stage

   Not phased

   Ages

   0 to 38

   Site

   Children's Hospital Colorado, Aurora, Colorado

   Locations

   6 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT06131801 on ClinicalTrials.gov

3. Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

   This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or…

   Stage

   Phase 1

   Ages

   0 to 21

   Site

   University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT02508038 on ClinicalTrials.gov

4. Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

   The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Stanford University Medical Center, Stanford, California

   Locations

   10 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT03618550 on ClinicalTrials.gov

5. AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

   Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.

   Stage

   Phase 2

   Ages

   0 to 30

   Site

   New York Medical College, Valhalla, New York

   Run by

   Mitchell Cairo

   See if you can join NCT04099966 on ClinicalTrials.gov

6. CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

   This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. Th…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT06059391 on ClinicalTrials.gov

7. A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

   This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cel…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT07020533 on ClinicalTrials.gov

8. Wisconsin Ginseng for Decreasing Cancer Related Fatigue

   This phase III trial compares the effect of Wisconsin ginseng (panax quinquefolius) to placebo in patients with cancer that suffer from significant fatigue. Fatigue is among the most challenging symptoms to manage in patients with cancer, both on or off active treatment. This symptom complex meanin…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota

   Locations

   15 in total

   Run by

   Mayo Clinic

   See if you can join NCT06395441 on ClinicalTrials.gov

9. AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

   This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Research Site, Duarte, California

   Locations

   38 in total

   Run by

   AstraZeneca

   See if you can join NCT06137144 on ClinicalTrials.gov

10. Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

    This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patie…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06398457 on ClinicalTrials.gov

11. Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

    This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not responded to treatment. Previous research combined antibodies and T cells to t…

    Stage

    Phase 1

    Ages

    12 to 75

    Site

    Houston Methodist Hospital, Houston, Texas

    Locations

    2 in total

    Run by

    Baylor College of Medicine

    See if you can join NCT06176690 on ClinicalTrials.gov

12. The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

    This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medica…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mayo Clinic in Florida, Jacksonville, Florida

    Run by

    Mayo Clinic

    See if you can join NCT07285044 on ClinicalTrials.gov

13. A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

    To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05615636 on ClinicalTrials.gov

14. Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

    This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).

    Stage

    Phase 1

    Ages

    18 to 100

    Site

    City of Hope, Duarte, California

    Locations

    7 in total

    Run by

    Marker Therapeutics, Inc.

    See if you can join NCT05798897 on ClinicalTrials.gov

15. Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies

    This is a phase 1 basket trial of TGFBR2 KO CAR27/IL-15 NK cells after lymphodepleting chemotherapy for patients with R/R B-NHL, HL, T-NHL or B-ALL.

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    The University of Texas M. D. Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT07444632 on ClinicalTrials.gov

16. Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

    The goal of this clinical research study is to learn if nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) can help to control newly diagnosed early-stage non-bulky cHL in pediatric, adolescent, and young adult patients. The safety of this drug combination will also be studied.

    Stage

    Phase 2

    Ages

    2 to 21

    Site

    UT MD Anderson, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT07551583 on ClinicalTrials.gov

17. Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma

    Pediatric patients receiving proton therapy for solid tumors or Hodgkin's lymphoma may experience anatomical changes during treatment that can affect proton therapy accuracy. This prospective single-arm study uses regular low-dose imaging to monitor these changes and adjust treatment plans as neede…

    Stage

    Not phased

    Ages

    Any age

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT07514819 on ClinicalTrials.gov

18. CD45BE-HSPC + CART-45 Cells

    This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as "CART-45 cells") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor ce…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Pennsylvania, Philadelphia, Pennsylvania

    Run by

    University of Pennsylvania

    See if you can join NCT07451054 on ClinicalTrials.gov

19. Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

    The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells.…

    Stage

    Phase 1

    Ages

    12 to 80

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05092451 on ClinicalTrials.gov

20. ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

    Despite the progress in the therapy, Hodgkin's Lymphoma (HL) remains fatal for more than 15% of patients. Even in patients who are cured, the morbidity of therapy is substantial and long-lasting. New therapeutic agents are required therefore not only to further reduce mortality but also to alleviat…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06090864 on ClinicalTrials.gov

21. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

    This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Florida Cancer Specialists - Lake Nona, Orlando, Florida

    Locations

    10 in total

    Run by

    Compass Therapeutics

    See if you can join NCT06150664 on ClinicalTrials.gov

22. Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

    This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole bra…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT06580002 on ClinicalTrials.gov

23. Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

    RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials …

    Stage

    Phase 3

    Ages

    16 to 69

    Site

    Stanford University - (Stanford Cancer Institute), Stanford, California

    Locations

    72 in total

    Run by

    University College, London

    See if you can join NCT04685616 on ClinicalTrials.gov

24. A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

    This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

    Stage

    Not phased

    Ages

    Any age

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    142 in total

    Run by

    Center for International Blood and Marrow Transplant Research

    See if you can join NCT01351545 on ClinicalTrials.gov

25. Familial Investigations of Childhood Cancer Predisposition

    NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor …

    Stage

    Not phased

    Ages

    Any age

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT03050268 on ClinicalTrials.gov